111 related articles for article (PubMed ID: 25385055)
1. Selumetinib for the treatment of cancer.
Ciombor KK; Bekaii-Saab T
Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract][Full Text] [Related]
3. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Dry JR; Pavey S; Pratilas CA; Harbron C; Runswick S; Hodgson D; Chresta C; McCormack R; Byrne N; Cockerill M; Graham A; Beran G; Cassidy A; Haggerty C; Brown H; Ellison G; Dering J; Taylor BS; Stark M; Bonazzi V; Ravishankar S; Packer L; Xing F; Solit DB; Finn RS; Rosen N; Hayward NK; French T; Smith PD
Cancer Res; 2010 Mar; 70(6):2264-73. PubMed ID: 20215513
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
8. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
9. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
Hedayat M; Jafari R; Majidi Zolbanin N
Clin Exp Med; 2023 Jun; 23(2):229-244. PubMed ID: 35171389
[TBL] [Abstract][Full Text] [Related]
11. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
12. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Davies BR; Logie A; McKay JS; Martin P; Steele S; Jenkins R; Cockerill M; Cartlidge S; Smith PD
Mol Cancer Ther; 2007 Aug; 6(8):2209-19. PubMed ID: 17699718
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract][Full Text] [Related]
14. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
16. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS
Kenney C; Kunst T; Webb S; Christina D; Arrowood C; Steinberg SM; Mettu NB; Kim EJ; Rudloff U
Invest New Drugs; 2021 Jun; 39(3):821-828. PubMed ID: 33405090
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
